Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01741701 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of Oxaloacetate in Subjects With Treated PD
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT01741701 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 33 participants.
The verdict
NCT01741701, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4 month period.
Interventions
- DRUG Placebo
- DRUG Oxaloacetate (OAA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01741701
The ClinicalTrials.gov registry entry for NCT01741701 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01741701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01741701 about?
NCT01741701 is a clinical study titled "A Pilot Study of Oxaloacetate in Subjects With Treated PD". The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4 month period.
What is the current status of trial NCT01741701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2012-12. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01741701?
The interventions under investigation include: Placebo (DRUG), Oxaloacetate (OAA) (DRUG).
Who is sponsoring clinical trial NCT01741701?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.